①Evaluate the safety, tolerability and pharmacokinetic (PK) characteristics of LN020 dry suspension after a single dose in healthy Chinese subjects; ②Compare the PK characteristics and safety of LN020 dry suspension and mabaloxavir tablets in healthy Chinese subjects; ③Evaluate the effect of food on the PK characteristics of LN020 dry suspension in healthy Chinese subjects.

Start Date15 Nov 2023

Sponsor / Collaborator

Shandong Luning Pharmaceutical Co., Ltd.

100 Clinical Results associated with LN-020

100 Translational Medicine associated with LN-020

100 Patents (Medical) associated with LN-020

Literatures (Medical) associated with LN-020

01 Oct 2016·Journal of UrologyQ1 · MEDICINE

Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures

Q1 · MEDICINE

Article

Author: Takhar, Mandeep ; Mitra, Anirban P. ; Buerki, Christine ; Seiler, Roland ; Black, Peter C. ; Erho, Nicholas ; Davicioni, Elai ; Lam, Lucia L. ; Skinner, Eila C. ; Daneshmand, Siamak

PURPOSEClinical staging in patients with muscle invasive bladder cancer misses up to 25% of lymph node metastasis. These patients are at high risk for disease recurrence and improved clinical staging is critical to guide management.MATERIALS AND METHODSWhole transcriptome expression profiles were generated in 199 patients who underwent radical cystectomy and extended pelvic lymph node dissection. The cohort was divided randomly into a discovery set of 133 patients and a validation set of 66. In the discovery set features were identified and modeled in a KNN51 (K-nearest neighbor classifier 51) to predict pathological lymph node metastases. Two previously described bladder cancer gene signatures, including RF15 (15-gene cancer recurrence signature) and LN20 (20-gene lymph node signature), were also modeled in the discovery set for comparison. The AUC and the OR were used to compare the performance of these signatures.RESULTSIn the validation set KNN51 achieved an AUC of 0.82 (range 0.71-0.93) to predict lymph node positive cases. It significantly outperformed RF15 and LN20, which had an AUC of 0.62 (range 0.47-0.76) and 0.46 (range 0.32-0.60), respectively. Only KNN51 showed significant odds of predicting LN metastasis with an OR of 2.65 (range 1.68-4.67) for every 10% increase in score (p <0.001). RF15 and LN20 had a nonsignificant OR of 1.21 (range 0.97-1.54) and 1.39 (range 0.52-3.77), respectively.CONCLUSIONSThe new KNN51 signature was superior to previously described gene signatures for predicting lymph node metastasis. If validated prospectively in transurethral resection of bladder tumor samples, KNN51 could be used to guide patients at high risk to early multimodal therapy.

100 Deals associated with LN-020

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza A virus infection	Phase 1	CN	Shandong Luning Pharmaceutical Co., Ltd.	15 Nov 2023
Influenza B virus infection	Phase 1	CN	Shandong Luning Pharmaceutical Co., Ltd.	15 Nov 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

LN-020

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation